1. Medicines
  2. Cardiology
  3. LEQVIO® (Inclisiran)
  4. Leqvio® resources

Click here for Prescribing Information

Leqvio® resources

December 15, 2022

Prescribing information

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Inclisiran is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.1

 

Leqvio® is not reimbursed in Ireland at this time.

 

Explore our growing repository of resources designed to provide useful information on Leqvio® and other relevant topics for healthcare professionals treating patients with ASCVD.

 

Rate this content: 
Average: 1.6 (23 votes)
Print
×

Ask Speakers

×

Medical Information Request

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: www.hpra.ie. Adverse events could also be reported to Novartis preferably via www.report.novartis.com or by email: [email protected] or by calling 01 2080 612.